Bimekizumab

Common card · No. 357723

Bimekizumab, sold under the brand name Bimzelx ( bim-ZEL-iks), is a humanized anti-IL17A, anti-IL-17F, and anti-IL17AF monoclonal antibody that is used to treat plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa. The most common side effects include upper respiratory tract infections (nose and throat infection) and oral candidiasis (thrush, a fungal infection in the mouth or throat). Injection site reactions were also common, reported in 3% of subjects. Bimekizumab was approved for medical use in the European Union in August 2021 and in the US in October 2023. In November 2024, bimekizumab was approved by the US Food and Drug Administration for the treatment of active moderate-to-severe hidradenitis suppurativa in adults.

Read on Wikipedia